Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular disease

This page shows the latest cardiovascular disease news and features for those working in and with pharma, biotech and healthcare.

AZ taps Ionis for another drug, this time in NASH

AZ taps Ionis for another drug, this time in NASH

It’s the third time AZ has taken up an option on an Ionis drug under a 2015 alliance in the area of cardiovascular, metabolic and kidney disease, after earlier deals ... for cardiovascular drug AZD8233 and kidney disease candidate AZD2373.

Latest news

  • Segmentation, evolved Segmentation, evolved

    Elias Zerhouni, Sanofi’s Global R&D head, pointed to Sanofi’s thinking when he said: “Not all patients with heart disease are the same. ... The data demonstrates that a precision-medicine approach in the field of cardiovascular disease may further

  • AZ adds another Ionis drug in $330m kidney disease deal AZ adds another Ionis drug in $330m kidney disease deal

    AZ adds another Ionis drug in $330m kidney disease deal. The candidate targets a genetically associated form of the condition. ... which started clinical trials in solid tumours last year, and AZD8233 for cardiovascular disease whose target is being kept

  • Arthritis patient group launches interactive video initiative Arthritis patient group launches interactive video initiative

    NRAS’ Love Your Heart educational initiative went live this week on Valentine’s Day to raise awareness of the increased risk of cardiovascular disease (CVD) for those with RA. ... Founder and CEO Ailsa Bosworth said: “It is still a relatively

  • AZ pushes harder into China with new joint venture AZ pushes harder into China with new joint venture

    Xiaolin Zhang, the current ICC head. The company’s starting portfolio includes candidates from AZ’s oncology, cardiovascular and metabolic disease and respiratory, said AZ.

  • J&J seeks US OK to add CV claim to Invokana label J&J seeks US OK to add CV claim to Invokana label

    Adults with type 2 diabetes are four times more likely to develop cardiovascular disease, and this is the leading cause of death in these patients. ... label in the wake of the EMPA-REG study, as well as Novo Nordisk’s GLP-1 agonist Victoza (liraglutide

More from news
Approximately 16 fully matching, plus 241 partially matching documents found.

Latest Intelligence

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    the low commercial value placed on antibiotic drugs compared to more lucrative sectors such as cardiovascular disease and cancer. ... By January 2018, the US Centers for Disease Control and Prevention had reported 29 cases of MCR resistance identified

  • Pharma deals continue to slide Pharma deals continue to slide

    Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen (J&J) and Xoma has licensed its interleukin 1 beta intellectual property for cardiovascular disease to Novartis plus ... Gevokizumab plus IP for use of IL-1 beta targeting

  • Perfecting the pharmaceutical pipeline with AI Perfecting the pharmaceutical pipeline with AI

    This has a knock-on effect for research around rare disease types specifically. ... For example, a drug being used for cardiovascular disease might be found to have useful qualities for neurological diseases.

  • The EarthWorks: New ways to improve patient care The EarthWorks: New ways to improve patient care

    Keeping people well and preventing illness. Technology is only interesting socially when it is boring technologically; we have to have scale to begin to prevent disease on a population level. ... cardiovascular disease and transplantation.

  • Deal Watch March 2016 Deal Watch March 2016

    Padlock's technology targets autoimmune disorders with protein/peptidyl arginine deiminase (PAD) inhibitors and offers the potential to prevent disease development in patients with early stage disease. ... Co-development. $130. Lipigon/ AstraZeneca.

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

  • Sanifit appoints Alexander Gold chief medical officer Sanifit appoints Alexander Gold chief medical officer

    Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others.

  • Leading Edge bolsters its delivery team Leading Edge bolsters its delivery team

    Francesca Worthington joins the group as an account manager after working across a variety of medical communication programmes and in a number of therapy areas, including haematology, ophthalmology, cardiovascular disease and

  • MyoKardia appoints COO and medical affairs VP MyoKardia appoints COO and medical affairs VP

    Prior to this, Dr Lee was therapeutic area head for cardiovascular, metabolic, respiratory and infectious disease programmes at Genentech. ... Their expertise and counsel will broaden our base of leadership and support our mission to change the world for

  • The Medicines Company appoints Biogen's Tony Kingsley The Medicines Company appoints Biogen's Tony Kingsley

    He will also serve at the company, which focuses on serious infectious disease care, acute cardiovascular care, and surgery and perioperative care, as its president, taking over from Glenn Sblendorio, who

  • MedImmune appoints Dr Christopher Rhodes MedImmune appoints Dr Christopher Rhodes

    AstraZeneca's biologics research and development arm MedImmune has appointed Dr Christopher Rhodes as vice president, cardiovascular and metabolic disease (CVMD) research. ... exciting time for our Cardiovascular and Metabolic Disease therapeutic area.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics